Disorders of Pulmonary Circulation: Pulmonary Hypertension

Disorders of Pulmonary Circulation

Introduction

Disorders of pulmonary circulation primarily affect the blood flow through the lungs, with Pulmonary Hypertension (PH) being a major pathological condition. PH is characterized by elevated pressure in the pulmonary arteries, leading to significant cardiovascular and respiratory complications.

Pulmonary Hypertension

Definition and Pathophysiology

• Pulmonary Hypertension (PH) is defined as an increase in blood pressure within the pulmonary arterial system.

• Key mechanisms include vasoconstriction, smooth muscle cell (SMC) proliferation, inflammation, and thrombosis.

• Multiple etiologies contribute to PH, including genetic, drug-induced, and disease-induced factors.

Classification of Pulmonary Hypertension

Groups and Etiologies

Pulmonary Hypertension is classified into five groups based on etiology and pathophysiology:

Group	Name	Common Etiologies
I	Pulmonary Arterial Hypertension (PAH)	Idiopathic, Heritable, Drug Induced, Disease Induced (HIV, portal HTN, connective tissue disorders)
II	Pulmonary HTN due to left heart disease	Left diastolic/systolic failure, Left valvular disorders
III	Pulmonary HTN due to lung disease/hypoxia	COPD, interstitial lung disease, Obstructive sleep apnea
IV	Chronic Thromboembolic Pulmonary HTN (CTEPH)	Chronic thrombotic/embolic disorders, Arteritis
V	Pulmonary HTN due to miscellaneous disorders	Sarcoidosis, Chronic kidney failure, Chronic hemolytic anemia

Group I PAH

Etiologies

• Idiopathic: No identifiable cause.

• Heritable: 70% of genetic cases are due to mutations in the bone morphogenetic protein receptor type II gene (BMPR2), which codes for TGF-β receptors that inhibit arterial SMC and endothelial cell proliferation.

• Drug Induced: Fenfluramine, dexfenfluramine, amphetamines, cocaine, some chemotherapy agents.

• Disease Induced: Associated with conditions such as HIV, portal hypertension, and connective tissue disorders.

Group II PAH

Secondary to Left Heart Disease

• Caused by left heart failure and mitral valve disorders (stenosis).

• Increased left atrial pressure leads to increased pulmonary venous and arterial pressure.

• Results in hypertrophy and thickening of pulmonary artery vessels, causing sustained pulmonary hypertension.

Group III PAH

Due to Lung Disease/Hypoxia

• Pulmonary circulation vasoconstricts in response to hypoxemia.

• Increased pulmonary artery pressure and resistance (afterload).

• Leads to right ventricular hypertrophy (early) and dilation (late), progressing to right ventricular failure.

Group IV PAH

Chronic Thromboembolic Pulmonary Hypertension

• Secondary to chronic thrombus/emboli.

• Impaired pulmonary circulation and hypoxemia.

Pathophysiology of Pulmonary Hypertension

Vascular Remodeling and Dysfunction

• Endothelial dysfunction and SMC proliferation are central to disease progression.

• Common features include increased pulmonary arteriole contractility, endothelial dysfunction, proliferation of endothelial and SMCs, microthrombi/emboli, and inflammatory mediator infiltration.

• End result: Vascular lumen narrows, increasing resistance.

Normal Regulation Pathways

Mechanisms of Pulmonary Endothelial Regulation

• Nitric Oxide (NO) Pathway: NO vasodilates, inhibits SMC proliferation, and platelet aggregation.

• Prostacyclin (PGI2)/Thromboxane (TBXA2) Pathway: PGI2 vasodilates, inhibits SMC proliferation, and platelet aggregation; TBXA2 vasoconstricts, stimulates SMC proliferation, and platelet aggregation.

• Endothelin-1 (ET) Pathway: ETA receptor (SMC) causes vasoconstriction, SMC proliferation/hypertrophy, and fibrosis; ETB receptor (SMC) causes vasoconstriction; ETB (endothelial cell) stimulates NO and PGI2 production.

Pathophysiology of PAH: Key Pathways

Nitric Oxide Pathway

• Decreased eNOS expression/activity leads to reduced NO production.

• Results in vasoconstriction, SMC proliferation, inflammation, platelet aggregation, and thrombosis.

Prostacyclin Pathway

• Shift toward increased Thromboxane A2 and decreased prostacyclin (PGI2).

• Results in vasoconstriction, SMC proliferation, inflammation, platelet aggregation, and thrombosis.

Endothelin-1 Pathway

• Increased ET-1 production.

• ETA and ETB expression on SMCs cause vasoconstriction, hypertrophy, proliferation, and fibrosis.

• ETB expression on endothelial cells stimulates NO and PGI2 production.

Clinical Presentation

Signs and Symptoms

• Signs of PAH: Elevated pulmonary artery mean pressure (>25 mmHg), pulmonary capillary wedge pressure (<15 mmHg), right ventricular hypertrophy, right atrial enlargement.

• Right Heart Failure: Lower extremity edema, abdominal edema, jugular venous distension (JVD), dyspnea, exertional chest pain.

• Progression to Left Heart Failure: Decreased cardiac output, fatigue, weakness, pulmonary edema, orthopnea.

Diagnosis

Diagnostic Criteria

• Diagnosis is based on clinical presentation and right heart catheterization.

• Key measurements:

  • Pulmonary artery mean pressure >25 mmHg

  • Pulmonary capillary wedge pressure <15 mmHg

Treatment of Pulmonary Arterial Hypertension (PAH)

Pharmacological Approaches

• Prostacyclin Analogs: Mimic PGI2 to promote vasodilation and inhibit SMC proliferation.

• Guanylate Cyclase Stimulators: Enhance NO signaling for vasodilation.

• Phosphodiesterase-5 Inhibitors: Increase cGMP levels, promoting relaxation and reduced proliferation.

• Endothelin-1 Receptor Antagonists: Block ETA/ETB receptors to reduce vasoconstriction and SMC proliferation.

Example: Drugs such as sildenafil (PDE-5 inhibitor), bosentan (endothelin receptor antagonist), and epoprostenol (prostacyclin analog) are used in PAH management.

Summary Table: Key Pathways and Effects

Pathway	Normal Effect	PAH Effect
Nitric Oxide	Vasodilation, inhibits SMC proliferation, platelet aggregation	↓ NO: Vasoconstriction, ↑ SMC proliferation, ↑ platelet aggregation
Prostacyclin (PGI2)	Vasodilation, inhibits SMC proliferation, platelet aggregation	↓ PGI2: Vasoconstriction, ↑ SMC proliferation, ↑ platelet aggregation
Thromboxane (TBXA2)	Vasoconstriction, stimulates SMC proliferation, platelet aggregation	↑ TBXA2: Enhanced vasoconstriction, SMC proliferation, platelet aggregation
Endothelin-1	ETA/ETB: Vasoconstriction, SMC proliferation/hypertrophy, fibrosis	↑ ET-1: Increased vasoconstriction, SMC proliferation, fibrosis

Key Equations

• Pulmonary Artery Pressure (PAP):

$PAP = (CO \times PVR) + PCWP$

• Where CO = Cardiac Output, PVR = Pulmonary Vascular Resistance, PCWP = Pulmonary Capillary Wedge Pressure.

Additional info:

• PAH is a progressive disease that can lead to right and left heart failure if untreated.

• Early diagnosis and targeted therapy are essential for improving patient outcomes.